koto_feja/E+ via Getty Images Geron Corporation (NASDAQ:GERN) could reach a turning point on June 16, 2024, after 34 years of its foundation. This date could represent the new company's commercial transformation. It could bring its unique product Imetelstat to new life on the real market and this drug could be able to bring real benefits to serious and highly disabling hematological diseases (MDS and MF). If we analyze the results of the IMerge Phase 3 clinical study we can see how there is statistical evid ...